Jbf Capital, Inc. Jounce Therapeutics, Inc. Transaction History

Jbf Capital, Inc.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2018 Aug 09, 2018	SELL	$7.27 - $21.88 $276,987 - $833,628	-38,100 Closed	0 $0
Q1 2018 May 11, 2018	BUY	$13.4 - $28.4 $510,540 - $1.08 Million	38,100 New	38,100 $852,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Jbf Capital, Inc., based on Form 13F filings with the SEC.

Stay updated on Jbf Capital, Inc. with notifications on news.